SilverCrest Metals
SILV
Cars.com
CARS
Lantheus
LNTH
Collegium Pharmaceutical
COLL
和黄医药
HCM
(Q3)2024/09/30 | (Q2)2024/06/30 | (Q1)2024/03/31 | (FY)2023/12/31 | (Q4)2023/12/31 | (Q3)2023/09/30 | (Q2)2023/06/30 | (Q1)2023/03/31 | (FY)2022/12/31 | (Q4)2022/12/31 | |
---|---|---|---|---|---|---|---|---|---|---|
营业总收入 | 66.29%5,837万 | 61.17%5,335.3万 | 82.51%4,453.9万 | 81.55%1.36亿 | 83.29%4,358.1万 | 72.50%3,510.2万 | 98.33%3,310.4万 | 71.90%2,440.4万 | 117.60%7,501.4万 | 134.53%2,377.7万 |
营业收入 | 66.29%5,837万 | 61.17%5,335.3万 | 82.51%4,453.9万 | 81.55%1.36亿 | 83.29%4,358.1万 | 72.50%3,510.2万 | 98.33%3,310.4万 | 71.90%2,440.4万 | 117.60%7,501.4万 | 134.53%2,377.7万 |
主营业务成本 | 32.23%2,145.9万 | 49.04%2,187.1万 | 63.73%1,950.5万 | 71.75%6,514.2万 | 70.41%2,232.6万 | 60.39%1,622.8万 | 78.85%1,467.5万 | 83.14%1,191.3万 | 103.83%3,792.9万 | 133.03%1,310.1万 |
毛利 | 95.57%3,691.1万 | 70.83%3,148.2万 | 100.42%2,503.4万 | 91.58%7,104.9万 | 99.09%2,125.5万 | 84.48%1,887.4万 | 117.17%1,842.9万 | 62.39%1,249.1万 | 133.75%3,708.5万 | 136.40%1,067.6万 |
营业费用 | 33.39%5,933.8万 | 32.36%5,831万 | 28.91%5,268.3万 | 52.98%1.8亿 | 42.27%5,081.2万 | 37.56%4,448.3万 | 67.12%4,405.4万 | 74.68%4,086.8万 | 68.23%1.18亿 | 67.31%3,571.6万 |
销售和管理费用 | 29.83%4,269.1万 | 25.79%4,080.9万 | 31.42%3,959.9万 | 48.35%1.32亿 | 39.49%3,631.6万 | 32.84%3,288.3万 | 65.05%3,244.1万 | 63.89%3,013.1万 | 74.05%8,882.8万 | 60.00%2,603.4万 |
研发费用 | 43.51%1,664.7万 | 50.70%1,750.1万 | 21.86%1,308.4万 | 67.16%4,844.6万 | 49.72%1,449.6万 | 52.99%1,160万 | 73.17%1,161.3万 | 114.27%1,073.7万 | 52.59%2,898.1万 | 90.74%968.2万 |
营业利润 | 12.43%-2,242.7万 | -4.69%-2,682.8万 | 2.57%-2,764.9万 | -35.24%-1.09亿 | -18.04%-2,955.7万 | -15.85%-2,560.9万 | -43.36%-2,562.5万 | -80.70%-2,837.7万 | -49.04%-8,072.4万 | -48.77%-2,504万 |
净非营业利息收入(费用) | 47.21%145.3万 | 253.53%120.2万 | 1,681.31%169.2万 | 232.39%355.6万 | 281.70%233.6万 | 294.29%98.7万 | 125.97%34万 | 92.78%-10.7万 | 53.16%-268.6万 | 139.18%61.2万 |
利息收入 | 29.26%259.3万 | 71.03%223.2万 | 251.35%273.7万 | 202.40%755.1万 | 134.17%346.1万 | 111.83%200.6万 | 888.64%130.5万 | --77.9万 | 3,185.53%249.7万 | 1,311.48%147.8万 |
利息费用 | 11.87%114万 | 6.74%103万 | 17.95%104.5万 | -22.92%399.5万 | 29.91%112.5万 | -29.97%101.9万 | -33.03%96.5万 | -40.18%88.6万 | -10.79%518.3万 | -39.86%86.6万 |
其他净收入(费用) | 92.44%-28.3万 | -8,420.00%-374.4万 | ||||||||
出售证券收益 | ---- | ---- | ---- | 62.19%-10.7万 | ---- | ---- | ---- | ---- | -242.21%-28.3万 | ---- |
特殊收入(费用) | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | ---325.8万 | ---- |
-减:其他特殊费用 | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --325.8万 | ---- |
其他非经营收入(费用) | ---- | ---- | ---- | 13.30%-17.6万 | ---- | ---- | ---- | ---- | -31.82%-20.3万 | ---- |
税前利润 | 14.82%-2,097.4万 | -1.35%-2,562.6万 | 8.87%-2,595.7万 | -21.51%-1.06亿 | 2.37%-2,750.4万 | -8.88%-2,462.2万 | -31.80%-2,528.5万 | -65.75%-2,848.4万 | -45.61%-8,715.4万 | -53.54%-2,817.2万 |
所得税 | ||||||||||
除税后利润 | 14.82%-2,097.4万 | -1.35%-2,562.6万 | 8.87%-2,595.7万 | -21.51%-1.06亿 | 2.37%-2,750.4万 | -8.88%-2,462.2万 | -31.80%-2,528.5万 | -65.75%-2,848.4万 | -45.61%-8,715.4万 | -53.54%-2,817.2万 |
持续经营利润 | 14.82%-2,097.4万 | -1.35%-2,562.6万 | 8.87%-2,595.7万 | -21.51%-1.06亿 | 2.37%-2,750.4万 | -8.88%-2,462.2万 | -31.80%-2,528.5万 | -65.75%-2,848.4万 | -45.61%-8,715.4万 | -53.54%-2,817.2万 |
归属于少数股东的净利润 | ||||||||||
归属于母公司的净利润 | 14.82%-2,097.4万 | -1.35%-2,562.6万 | 8.87%-2,595.7万 | -21.51%-1.06亿 | 2.37%-2,750.4万 | -8.88%-2,462.2万 | -31.80%-2,528.5万 | -65.75%-2,848.4万 | -45.61%-8,715.4万 | -53.54%-2,817.2万 |
优先股派息 | ||||||||||
其他优先股派息 | ||||||||||
归属于普通股股东的净利润 | 14.82%-2,097.4万 | -1.35%-2,562.6万 | 8.87%-2,595.7万 | -21.51%-1.06亿 | 2.37%-2,750.4万 | -8.88%-2,462.2万 | -31.80%-2,528.5万 | -65.75%-2,848.4万 | -45.61%-8,715.4万 | -53.54%-2,817.2万 |
基本每股收益 | 21.57%-0.4 | 10.71%-0.5 | 19.05%-0.51 | -14.29%-2.24 | 14.29%-0.54 | 0.00%-0.51 | -30.23%-0.56 | -61.54%-0.63 | 46.01%-1.96 | -50.00%-0.63 |
稀释每股收益 | 21.57%-0.4 | 10.71%-0.5 | 19.05%-0.51 | -14.29%-2.24 | 14.29%-0.54 | 0.00%-0.51 | -30.23%-0.56 | -61.54%-0.63 | 46.01%-1.96 | -50.00%-0.63 |
每股派息 | ||||||||||
货币单位 | 美元 | 美元 | 美元 | 美元 | 美元 | 美元 | 美元 | 美元 | 美元 | 美元 |
会计准则 | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
审计意见 | -- | -- | -- | 无保留意见 | -- | -- | -- | -- | 无保留意见 | -- |